Ara-C3燐酸の人白血病細胞内動態からみたara-C投与法の基礎的検討
スポンサーリンク
概要
著者
関連論文
- VP-16耐性ヒト白血病細胞株に対するアンソラサイクリン系新抗腫瘍剤 Idarubicin (IDA) の抗腫瘍効果
- シンポジウム1難治性白血病の治療-現況と将来の展望 抗白血病薬-新薬と合理的投与法の試みー
- ara-Cを,中等量療法にて長期,反復投与し完治を得たと考えられる急性骨髄性白血病(M1)の1例
- Cytosine Arabinoside (ara-C) 少量療法における薬物動態
- 平成4年度日本臨床薬理学会海外研修員報告書 : その4(研修完了報告書)
- Ara-C3燐酸の人白血病細胞内動態からみたara-C投与法の基礎的検討
- 急性白血病における中等量ara-C療法の薬理学的検討
- Plasma drug level maintenance and its mechanism during intravenous administration of behenoyl-arabinofuranosyl cytosine (BHAC).
- Effects of 6-mercaptopurine(6MP) for the metabolism in a cell of 1-.BETA. - D arabinofuranosylcytosine(ara-C).
- Clinical effect of rhG-CSF (KRN8601) for infectious disease in hematopoietic tumor patient.
- A difference in time-dependent morphological change of L1210 cell by daunorubicin and Cytosine Arabinoside.
- Incorporation and DNA damage by Cytosine arabinoside in L1210 cell.
- Study of action potentiation factor by Ara-C.On combined use of anthracycline.
- Antitumor effect of Ara-C analogue of difluorodeoxytidine(dFdC) from the viewpoint of pharmacological action.
- Effect of combined use of nucleoside for cellular accumulation and activation of Cytosine arabinoside.
- Cytosine Arabinoside 少量皮下投与の薬物動態
- Studies of antitumor effect of 4-carbamoylimidazolium-5-olate (SM-108) on leukemic cells and its enhancement by dipyridamole.
- Studies on the optimal dosage for activation of cytosine arabinoside (ara-C).
- Distribution of antitumor drugs in plasma and blood cells, and their pharmacokinetics.